PMV Pharmaceuticals (PMVP) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($248.4 million vs $112.5 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMVP | VCRE |
|---|---|---|
| Share price | $1.49 | $8.82 |
| Market cap | $112.51M | $248.41M |
| 1-day change | -0.67% | +1.85% |
| YTD return | +19.20% | — |
| 1-year return | +4.93% | — |
| 5-year return | -93.78% | — |
| EPS (TTM) | $-1.42 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.91 | $17.80 |
| 52-week low | $1.02 | $7.88 |
| Distance from 52-week high | -21.99% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +181.88% | +275.96% |
| Average volume | 661.39K | 16.22K |
| Shares outstanding | 75.51M | 28.16M |
| Employees | 54 | 46 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vicore Pharma AB is about 2.2 times larger than PMV Pharmaceuticals by market value ($248.41M vs $112.51M).
- The two companies sit in different sectors: PMV Pharmaceuticals in Healthcare and Vicore Pharma AB in Health Care.
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Healthcare · Biotechnology · 54 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
PMVP vs VCRE FAQ
Which is bigger, PMV Pharmaceuticals or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $248.41M compared with $112.51M for PMV Pharmaceuticals (PMVP).
Are PMV Pharmaceuticals and Vicore Pharma AB in the same industry?
No. PMV Pharmaceuticals is in the Healthcare sector, while Vicore Pharma AB is in Health Care.